The market in the first quarter of 2022 has ended. As of the closing on March 31, the Shanghai Composite Index has fallen by 10.65%, the Shenzhen composite index has fallen by 18.44% and the gem index has fallen by 19.96%. The main reason for the sharp decline of the index is the decline of some heavyweight stocks and track institutional stocks. Although it is uncertain whether institutional stocks can stop falling, stabilize or even rebound in the future, in the environment of collective sharp decline of institutional stocks, some stocks still actively investigated by many institutions may be expected to become the target of bottom reading of institutional funds. Now let’s take stock of the top 20 stocks with the largest number of institutional research and the top 20 stocks with the largest number of institutional research in the first quarter.
According to the data in the above table, the 20 stocks with the largest number of institutional research in the first quarter received at least more than 500 institutional research. From the industry sectors to which these stocks belong, the number of stocks in the pharmaceutical and medical sector accounted for the highest among the top 20 stocks, and the pharmaceutical sector was also one of the sectors with the best market performance in the first quarter. Shanghai Junshi Biosciences Co.Ltd(688180) increased by 30.17% in the first quarter, which was the largest increase among the top 20 stocks. In addition to the pharmaceutical sector, the rest of the top 20 stocks belong to a messy sector.
In terms of specific stocks, Thunder Software Technology Co.Ltd(300496) in the first quarter, the largest number of institutions were surveyed, and a total of 1787 institutions surveyed the company. The company is the world’s leading provider of intelligent operating system products and technologies. The company is mainly concerned by institutions because of its business in the field of intelligent driving vehicles. The company is also one of the leaders of intelligent driving concept stocks in the A-share market.
In a recent survey, the company said that the company’s intelligent cockpit business has established a leading position in the world, ranging from chip platform to software products and functions, human-computer interaction experience and cockpit and driving cross domain development. The company has more than 1000 independently developed technology patents and software copyrights, and has about 3800 employees worldwide, of which R & D personnel account for nearly 90%.
Capital Securities recently released a research report on the company, saying that the company has a clear card position, an excellent track, and has technical barriers and core competitive advantages. With the mitigation of factors such as lack of core, the high growth trend is expected to continue in the next few years. At the same time, strengthening the technology research and development of intelligent vehicles and intelligent Internet of things will consolidate the leading advantage of the company in the industry
Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) in the first quarter, it was surveyed by 1630 institutions, including bocom Schroeder fund, Ningbo magic square quantification, Nomura International (Hong Kong), freshwater spring and other well-known institutions. As one of the leading companies in the medical device industry, the company has always been the favored object of institutional research. It is also one of the heavy positions of star fund managers such as Ge Lan and Zhang Kun.
Guolian Securities Co.Ltd(601456) recently released the company’s research report, saying that we believe that after Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) covid-19, we will enjoy the acceleration of global layout and the business cycle of China’s new infrastructure, and the performance can grow continuously and stably. According to the relative valuation and absolute valuation, considering the scarcity of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) equipment scarcity leader and the ability of global expansion, the company is given 52 times PE valuation, corresponding to the target price of 450 yuan. The closing price of the stock in the first quarter was 307 yuan, up 46.5% from the target price.
From the top 20 stocks in the first quarter of the above table, the pharmaceutical industry is still the largest industry sector. It can be seen that the pharmaceutical industry is one of the most favored industries for institutional research in the first quarter, both in terms of the number of institutional researchers and the number of institutional research. In addition, in the first quarter, there were two bank stocks among the top 20 stocks surveyed by institutions, namely Jiangsu Zhangjiagang Rural Commercial Bank Co.Ltd(002839) and Bank Of Hangzhou Co.Ltd(600926) , which were rarely surveyed by institutions with such a high frequency. It is worth noting that both bank stocks rose against the trend in the first quarter and significantly outperformed the index.
Yunnan Baiyao Group Co.Ltd(000538) in the first quarter, there were 20 institutional surveys, which was the stock that received the most institutional surveys in the first quarter. Although Chinese medicine stocks generally performed well in the first quarter, as one of the leaders of Chinese medicine stocks, the company’s share price fell by 21.82% in the first quarter, significantly outperforming the industry average.
While stabilizing the traditional main business, since last year, the company has concentrated advantageous resources and actively promoted the ecological layout of the medical and American industrial chain. The company continues to make efforts in the medical beauty strategy track, accurately customize the skin management industry and skin medical outpatient institutions, and provide differentiated solutions for users with different needs under the collaborative development logic within the group.
In addition, in March 2022, the company decided to increase Shanghai Pharmaceuticals Holding Co.Ltd(601607) with the approval of the CSRC, invested 14.38 billion yuan and sent two directors to the Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of directors. With the help of Shanghai Pharmaceuticals Holding Co.Ltd(601607) high-quality platform and industrial resource coordination, further amplify Yunnan Baiyao Group Co.Ltd(000538) existing resource advantages and grasp the important opportunities of industrial integration.
Southwest Securities Co.Ltd(600369) recently released the company’s research report, which said that considering the continuous improvement of the company’s four major businesses, the stable leading position of orthopedics and traumatology drugs, the equity incentive plan to stimulate the enthusiasm of employees, and the continuous implementation of new products and projects in the field of toothpaste and skin care, the company’s future growth can be expected.
